A new study by Gary Sachs and team showed that adults with major depressive disorder and poor response to antidepressants alone were treated with adjunctive cariprazine at a dose of 1.5 mg/day, which showed effectiveness in lowering depressed symptoms. The findings of this study were published in The American journal of Psychiatry.
Adults with severe depressive illness with poor response to antidepressants alone were randomized in this double-blind, placebo-controlled research in a 1:1:1 ratio to placebo, cariprazine at 1.5 mg/day, or cariprazine at 3.0 mg/day. The Montgomery-Sberg Depression Rating Scale total score change from baseline to week six was the main result (MADRS). In the modified intent-to-treat (mITT) population, least-squares mean differences were calculated using a mixed-effects model for repeated measurements with multiple comparisons correction.
The key findings of this study were;
The mITT group comprised 751 individuals (placebo: N=249; cariprazine 1.5 mg/day: N=250; cariprazine 3.0 mg/day: N=252).
In week 6, cariprazine 1.5 mg/day substantially outperformed placebo in terms of mean decrease from baseline in MADRS total score (14.1 vs. 11.5), but not cariprazine 3.0 mg/day (13.1).
In weeks 2 and 4, there were significant differences between the cariprazine 1.5 mg/day and placebo groups.
Patients receiving cariprazine 1.5 mg/day were substantially more likely than placebo-treated individuals to meet the MADRS response criteria (44.0% vs. 34.9%); remission rates were not statistically different between groups.
Akathisia and nausea were frequent treatment-emergent side effects (5% in either cariprazine group and double the incidence of placebo).
In conclusion, Cariprazine had a safety profile that was consistent with earlier findings, and it was typically well tolerated.
Reference:
Sachs, G. S., Yeung, P. P., Rekeda, L., Khan, A., Adams, J. L., & Fava, M. (2023). Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. In American Journal of Psychiatry (Vol. 180, Issue 3, pp. 241–251). American Psychiatric Association Publishing. https://doi.org/10.1176/appi.ajp.20220504
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.